Two oral presentations at AHA Hypertension 2026 will highlight the antihypertensive efficacy of aprocitentan in two hypertension populations from the PRECISION study: patients with obesity and patients across… read more.
Edwards Lifesciences announced that the U.S. Food and Drug Administration (FDA) has approved the Autus Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital… read more.
Drones could be used to deliver automated external defibrillators (AEDs) to where a person is suffering an out-of-hospital cardiac arrest, according to a study presented at the European… read more.
Medtronic announced regulatory milestones for software used with two cardiac ablation platforms. This includes FDA clearance and CE Mark for the latest Affera Prism-2 Mapping Software. The company… read more.
Bristol Myers Squibb announced that the FDA approved CAMZYOS (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and… read more.
Researchers from Oxford Population Health analysed clinic blood pressure measurements collected by Our Future Health, the UK’s largest health research programme, from participants who enrolled between 2022 and… read more.
Exercise-based cardiac rehabilitation reduces hospital admissions by a third and heart attack risk by more than a quarter, as well as remaining beneficial in the long term, a… read more.
Where a patient undergoes heart surgery can significantly affect their risk of infection following the procedure, with some patients facing more than double the risk of others, according… read more.
People with atrial fibrillation have signs of the condition in the retinas of their eyes that can be detected as early as four years before diagnosis, finds a… read more.
BridgeBio Pharma, Inc. presented new analyses from the Phase 3 ATTRibute-CM study of Attruby (acoramidis) in transthyretin amyloid cardiomyopathy (ATTR-CM), including the cardiac magnetic resonance imaging (CMR) substudy… read more.
BridgeBio Pharma, Inc. announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study designed to further characterize the long-term effects of acoramidis on the… read more.
Abbott announced it has received CE Mark for the Amulet 360 Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce risk of stroke in patients with… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
